Salbutamol Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:418791908
Width:200
Chirality:Racemic mixture
Usan:Albuterol
Tradename:Ventolin, Proventil, ProAir, others
Dailymedid:Albuterol
Pregnancy Au:A
Pregnancy Au Comment:[1] [2]
Routes Of Administration:By mouth, Inhalational, Intravenous
Class:Beta2-adrenergic agonist
Atc Prefix:R03
Atc Suffix:AC02
Legal Au:S3/S4
Legal Au Comment:[3]
Legal Ca:Rx-only
Legal Ca Comment:[4] [5]
Legal Nz:Prescription only
Legal Uk:POM
Legal Us:Rx-only
Metabolism:Liver
Elimination Half-Life:3.8–6 hrs (inhaled); 5–7.2 hrs (pill)
Excretion:Kidney
Onset:<15 min (inhaled), <30 min (pill)
Duration Of Action:3–6 hrs (inhaled); up to 8 hrs (pill)
Cas Number:18559-94-9
Pubchem:2083
Pubchemsubstance:46505312
Iuphar Ligand:558
Drugbank:DB01001
Chemspiderid:1999
Unii:QF8SVZ843E
Kegg:D02147
Chebi:2549
Chembl:714
Iupac Name:(RS)-4-[2-(''tert''-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
C:13
H:21
N:1
O:3
Smiles:CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
Stdinchi:1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
Stdinchikey:NDAUXUAQIAJITI-UHFFFAOYSA-N

Salbutamol, also known as albuterol and sold under the brand name Ventolin among others, is a medication that opens up the medium and large airways in the lungs.[6] It is a short-acting β2 adrenergic receptor agonist that causes relaxation of airway smooth muscle. It is used to treat asthma, including asthma attacks and exercise-induced bronchoconstriction, as well as chronic obstructive pulmonary disease (COPD).[6] It may also be used to treat high blood potassium levels.[7] Salbutamol is usually used with an inhaler or nebulizer, but it is also available in a pill, liquid, and intravenous solution.[6] [8] Onset of action of the inhaled version is typically within 15 minutes and lasts for two to six hours.[6]

Common side effects include shakiness, headache, fast heart rate, dizziness, and feeling anxious.[6] Serious side effects may include worsening bronchospasm, irregular heartbeat, and low blood potassium levels.[6] It can be used during pregnancy and breastfeeding, but safety is not entirely clear.[6] [9]

Salbutamol was patented in 1966 in Britain and became commercially available in the UK in 1969.[10] [11] It was approved for medical use in the United States in 1982.[6] It is on the World Health Organization's List of Essential Medicines.[12] Salbutamol is available as a generic medication.[6] In 2021, it was the seventh most commonly prescribed medication in the United States, with more than 61million prescriptions.[13] [14]

Medical uses

Salbutamol is typically used to treat bronchospasm (due to any cause—allergic asthma or exercise-induced), as well as chronic obstructive pulmonary disease. It is also one of the most common medicines used in rescue inhalers (short-term bronchodilators to alleviate asthma attacks).[15]

As a β2 agonist, salbutamol also has use in obstetrics. Intravenous salbutamol can be used as a tocolytic to relax the uterine smooth muscle to delay premature labor. While preferred over agents such as atosiban and ritodrine, its role has largely been replaced by the calcium channel blocker nifedipine, which is more effective and better tolerated.[16]

Salbutamol has been used to treat acute hyperkalemia, as it stimulates potassium flow into cells, thus lowering the potassium in the blood.[7]

Two recent studies have suggested that salbutamol reduces the symptoms of newborns and adolescents with myasthenia gravis and transient neonatal myasthenia gravis.[17] [18]

Adverse effects

The most common side effects are fine tremor, anxiety, headache, muscle cramps, dry mouth, and palpitation.[19] Other symptoms may include tachycardia, arrhythmia, flushing of the skin, myocardial ischemia (rare), and disturbances of sleep and behaviour.[19] Rarely occurring, but of importance, are allergic reactions of paradoxical bronchospasms, urticaria (hives), angioedema, hypotension, and collapse. High doses or prolonged use may cause hypokalemia, which is of concern especially in patients with kidney failure and those on certain diuretics and xanthine derivatives.[19]

Salbutamol metered dose inhalers have been described as the "single biggest source of carbon emissions from NHS medicines prescribing" due to the propellants used in the inhalers. Dry powder inhalers are recommended as a low-carbon alternative.[20]

Pharmacology

The tertiary butyl group in salbutamol makes it more selective for β2 receptors,[21] which are the predominant receptors on the bronchial smooth muscles. Activation of these receptors causes adenylyl cyclase to convert ATP to cAMP, beginning the signalling cascade that ends with the inhibition of myosin phosphorylation and lowering the intracellular concentration of calcium ions (myosin phosphorylation and calcium ions are necessary for muscle contractions). The increase in cAMP also inhibits inflammatory cells in the airway, such as basophils, eosinophils, and most especially mast cells, from releasing inflammatory mediators and cytokines.[22] Salbutamol and other β2 receptor agonists also increase the conductance of channels sensitive to calcium and potassium ions, leading to hyperpolarization and relaxation of bronchial smooth muscles.[23]

Salbutamol is either filtered out by the kidneys directly or is first metabolized into the 4′-O-sulfate, which is excreted in the urine.

Chemistry

Salbutamol is sold as a racemic mixture. The (R)-(−)-enantiomer (CIP nomenclature) is shown in the image at right (top), and is responsible for the pharmacologic activity; the (S)-(+)-enantiomer (bottom) blocks metabolic pathways associated with elimination of itself and of the pharmacologically active enantiomer (R).[24] The slower metabolism of the (S)-(+)-enantiomer also causes it to accumulate in the lungs, which can cause airway hyperreactivity and inflammation.[25] Potential formulation of the R form as an enantiopure drug is complicated by the fact that the stereochemistry is not stable, but rather the compound undergoes racemization within a few days to weeks, depending on pH.[26]

The direct separation of Salbutamol enantiomers and the control of enantiomeric purity has been described by thin-layer chromatography.[27]

History

Salbutamol was discovered in 1966, by a team led by David Jack at the Allen and Hanburys laboratory (now a subsidiary of Glaxo) in Ware, Hertfordshire, England, and was launched as Ventolin in 1969.[28]

The 1972 Munich Olympics were the first Olympics where anti-doping measures were deployed, and at that time β2 agonists were considered to be stimulants with high risk of abuse for doping. Inhaled salbutamol was banned from those games, but by 1986 was permitted (although oral β2 agonists were not). After a steep rise in the number of athletes taking β2 agonists for asthma in the 1990s, Olympic athletes were required to provide proof that they had asthma in order to be allowed to use inhaled β2 agonists.[29]

In February 2020, the U.S. Food and Drug Administration (FDA) approved the first generic of an albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm in people four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in people four years of age and older.[30] [31] The FDA granted approval of the generic albuterol sulfate inhalation aerosol to Perrigo Pharmaceutical.

In April 2020, the FDA approved the first generic of Proventil HFA (albuterol sulfate) metered dose inhaler, 90 μg per inhalation, for the treatment or prevention of bronchospasm in patients four years of age and older who have reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group.[32] The FDA granted approval of this generic albuterol sulfate inhalation aerosol to Cipla Limited.

Society and culture

In 2020, generic versions were approved in the United States.

Names

Salbutamol is the international nonproprietary name (INN) while albuterol is the United States Adopted Name (USAN).[33] The drug is usually manufactured and distributed as the sulfate salt (salbutamol sulfate).

It was first sold by Allen & Hanburys (UK) under the brand name Ventolin, and has been used for the treatment of asthma ever since.[34] The drug is marketed under many names worldwide.[35]

Misuse

Albuterol and other beta-2 adrenergic agonists are used by some recreational bodybuilders.[36] [37]

Doping

there was no evidence that an increase in physical performance occurs after inhaling salbutamol, but there are various reports for benefit when delivered orally or intravenously.[38] [39] In spite of this, salbutamol required "a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions" under the 2010 WADA prohibited list. This requirement was relaxed when the 2011 list was published to permit the use of "salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers' recommended therapeutic regimen."[40] [41]

Abuse of the drug may be confirmed by detection of its presence in plasma or urine, typically exceeding 1,000 ng/mL. The window of detection for urine testing is on the order of just 24 hours, given the relatively short elimination half-life of the drug,[42] [43] [44] estimated at between 5 and 6 hours following oral administration of 4 mg.[45]

Research

Salbutamol has been studied in subtypes of congenital myasthenic syndrome associated with mutations in Dok-7.[46]

It has also been tested in a trial aimed at treatment of spinal muscular atrophy; it is speculated to modulate the alternative splicing of the SMN2 gene, increasing the amount of the SMN protein, the deficiency of which is regarded as a cause of the disease.[47] [48]

Albuterol increases energy expenditure by 10-15 percent at a therapeutic dose for asthma and around 25 percent at a higher, oral dose. In several human studies, albuterol increased lean body mass, reduced fat mass, and caused lipolysis; it has been studied for use as an anti-obesity and anti-muscle wasting medication when taken orally.[49] [50]

Veterinary use

Salbutamol's low toxicity makes it safe for other animals and thus is the medication of choice for treating acute airway obstruction in most species. It is usually used to treat bronchospasm or coughs in cats and dogs and used as a bronchodilator in horses with recurrent airway obstruction; it can also be used in emergencies to treat asthmatic cats.[51] [52]

Toxic effects require an extremely high dose, and most overdoses are due to dogs chewing on and puncturing an inhaler or nebulizer vial.[53]

Notes and References

  1. Web site: Prescribing medicines in pregnancy database . Thereaputic Goods Administration . Australian Government . 19 December 2018 .
  2. Web site: Albuterol Use During Pregnancy . Drugs.com . 8 March 2019 . 21 December 2019.
  3. Web site: Poisons Standard October 2017. Thereaputic Goods Administration . Australian Government.
  4. Web site: Prescription Drug List. 23 October 2014. Government of Canada.
  5. Web site: Respiratory health . . 9 May 2018 . 13 April 2024.
  6. Web site: Albuterol. Drugs.com. The American Society of Health-System Pharmacists. https://web.archive.org/web/20151208181121/http://www.drugs.com/monograph/albuterol.html. 8 December 2015. live. 2 December 2015.
  7. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM . Emergency interventions for hyperkalaemia . The Cochrane Database of Systematic Reviews . 2 . CD003235 . April 2005 . 2005 . 15846652 . 10.1002/14651858.CD003235.pub2 . 6457842 .
  8. Starkey ES, Mulla H, Sammons HM, Pandya HC . Intravenous salbutamol for childhood asthma: evidence-based medicine? . Archives of Disease in Childhood . 99 . 9 . 873–7 . September 2014 . 24938536 . 10.1136/archdischild-2013-304467 . 2070868 . https://web.archive.org/web/20170908175627/https://derbyhospitals-nhs.archive.knowledgearc.net/bitstream/handle/123456789/297/%2814%29%20Arch%20Dis%20Child.pdf?sequence=1&isAllowed=y . dead . 8 September 2017 .
  9. Book: Yaffe SJ . Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 2011. Wolters Kluwer Health/Lippincott Williams & Wilkins . Philadelphia . 9781608317080 . 32 . 9th . live. https://web.archive.org/web/20151208061118/https://books.google.ca/books?id=OIgTE4aynrMC&pg=PA32 . 8 December 2015.
  10. Book: Landau R . Pharmaceutical innovation: revolutionizing human health . 1999 . Chemical Heritage Press . Philadelphia . 9780941901215 . 226 . live . https://web.archive.org/web/20151208072936/https://books.google.ca/books?id=IH4lPs6S1bMC&pg=PA226 . 8 December 2015.
  11. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2006 . John Wiley & Sons . 9783527607495 . 542 .
  12. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 21st list 2019 . 2019 . 10665/325771 . World Health Organization . World Health Organization . Geneva . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO . free .
  13. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  14. Web site: Albuterol - Drug Usage Statistics . ClinCalc . 14 January 2024.
  15. Web site: Hatfield H . Asthma: The Rescue Inhaler -- Now a Cornerstone of Asthma Treatment . WebMD . 27 June 2017 . live . https://web.archive.org/web/20170716061632/http://www.webmd.com/asthma/features/asthma-rescue-inhaler-cornerstone-asthma-treatment . 16 July 2017 .
  16. Book: Australian Medicines Handbook. Rossi S . AMH. 2004. 978-0-9578521-4-3.
  17. Allen NM, Hacohen Y, Palace J, Beeson D, Vincent A, Jungbluth H . Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome . Neurology . 86 . 7 . 692–4 . February 2016 . 26791147 . 4762416 . 10.1212/WNL.0000000000002382 .
  18. Allen NM, O'Rahelly M, Eymard B, Chouchane M, Hahn A, Kearns G, Kim DS, Byun SY, Nguyen CE, Schara-Schmidt U, Kölbel H, Marina AD, Schneider-Gold C, Roefke K, Thieme A, Van den Bergh P, Avalos G, Álvarez-Velasco R, Natera-de Benito D, Cheng MH, Chan WK, Wan HS, Thomas MA, Borch L, Lauzon J, Kornblum C, Reimann J, Mueller A, Kuntzer T, Norwood F, Ramdas S, Jacobson LW, Jie X, Fernandez-Garcia MA, Wraige E, Lim M, Lin JP, Claeys KG, Aktas S, Oskoui M, Hacohen Y, Masud A, Leite MI, Palace J, De Vivo D, Vincent A, Jungbluth H . The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD) . Brain: A Journal of Neurology . 146 . 10 . 4233–4246 . October 2023 . 37186601 . 10545502 . 10.1093/brain/awad153 .
  19. Book: British National Formulary . . London . March 2008 . 57 . 3.1.1.1 Selective beta2 agonists – side effects . 978-0-85369-778-7 . registration . https://archive.org/details/britishnationalf0000unse_k4e9 .
  20. News: Primary care networks incentivised to switch patients to more environmentally friendly inhalers . 16 October 2021 . Pharmaceutical Journal . 3 September 2021.
  21. Book: Foye's Principles of Medicinal Chemistry. Lemke TL, Williams DA, Roche VF, Zito SW . 2013. Lippincott Williams & Wilkins. 9781609133450. Philadelphia, PA. 1314–1320. 748675182. live. https://web.archive.org/web/20170908175627/https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1315. 8 September 2017.
  22. Book: Papich MG . Saunders Handbook of Veterinary Drugs . Albuterol Sulfate . St. Louis, Mo . 2007 . 2nd . Saunders/Elsevier . 9781416028888 . 10–11.
  23. Web site: US Department of Health and Human Services . Albuterol - Medical Countermeasures Database . CHEMM . 23 June 2017 . 28 April 2017 . live . https://web.archive.org/web/20170803045423/https://chemm.nlm.nih.gov/countermeasure_albuterol.htm . 3 August 2017 .
  24. Web site: Medicinal Chemistry of the Peripheral Nervous System – Adrenergics and Cholinergics their Biosynthesis, Metabolism, and Structure Activity Relationships. Mehta A . https://web.archive.org/web/20101104022742/http://pharmaxchange.info/notes/medicinal_chemistry/adrenergics_cholinergics.html . 4 November 2010. dead. 20 October 2010.
  25. Web site: Inhalation Therapy of Airway Disease . Merck Veterinary Manual . 22 June 2017 . live . https://web.archive.org/web/20170625203315/http://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-respiratory-system/inhalation-therapy-of-airway-disease . 25 June 2017 .
  26. Biol Pharm Bull . 1 September 2017 . 40 . 9 . 1374–1380 . 10.1248/bpb.b17-00067 . Study of pH Stability of R-Salbutamol Sulfate Aerosol Solution and Its Antiasthmatic Effects in Guinea Pigs . Liu Q, Li Q, Han T, Hu T, Zhang X, Hu J, Hu H, Tan W . 28652557. free .
  27. Bhushan R, Tanwar S . Different approaches of impregnation for resolution of enantiomers of atenolol, propranolol and salbutamol using Cu(II)-L-amino acid complexes for ligand exchange on commercial thin layer chromatographic plates . Journal of Chromatography A . 1217 . 8 . 1395–8 . February 2010 . 20074739 . 10.1016/j.chroma.2009.12.071 .
  28. News: Sir David Jack, who has died aged 87, was the scientific brain behind the rise of the pharmaceuticals company Glaxo. The Telegraph. 17 November 2011. live. https://web.archive.org/web/20111125011155/http://www.telegraph.co.uk/news/obituaries/finance-obituaries/8897458/Sir-David-Jack.html. 25 November 2011.
  29. Fitch KD . beta2-Agonists at the Olympic Games . Clinical Reviews in Allergy & Immunology . 31 . 2–3 . 259–68 . 2006 . 17085798 . 10.1385/CRIAI:31:2:259 . 71908898 .
  30. FDA approves first generic of ProAir HFA . U.S. Food and Drug Administration (FDA) . 24 February 2020 . 24 February 2020.
  31. Web site: Albuterol Sulfate: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 26 February 2020.
  32. FDA Approves First Generic of a Commonly Used Albuterol Inhaler to Treat and Prevent Bronchospasm . U.S. Food and Drug Administration (FDA) . 8 April 2020 . 10 April 2020.
  33. Web site: Salbutamol . PubChem . U.S. National Library of Medicine .
  34. Ventolin remains a breath of fresh air for asthma sufferers, after 40 years . The Pharmaceutical Journal . 279 . 7473 . 404–405. https://web.archive.org/web/20071015201448/http://www.pharmj.com/pdf/articles/pj_20071013_landmarkdrugs01.pdf. 15 October 2007.
  35. Web site: Salbutamol. Drugs.com. https://web.archive.org/web/20160330054502/http://www.drugs.com/international/salbutamol.html. 30 March 2016. live. 11 April 2016.
  36. Jessen S, Reitelseder S, Kalsen A, Kreiberg M, Onslev J, Gad A, Ørtenblad N, Backer V, Holm L, Bangsbo J, Hostrup M . β2-Adrenergic agonist salbutamol augments hypertrophy in MHCIIa fibers and sprint mean power output but not muscle force during 11 weeks of resistance training in young men . Journal of Applied Physiology . 130 . 3 . 617–626 . March 2021 . 33357007 . 10.1152/japplphysiol.00553.2020 . 229695809 .
  37. Ip EJ, Doroudgar S, Lau B, Barnett MJ . Anabolic steroid users' misuse of non-traditional prescription drugs . Research in Social & Administrative Pharmacy . 15 . 8 . 949–952 . August 2019 . 31303195 . 10.1016/j.sapharm.2018.07.003 . 81614300 .
  38. Pluim BM, de Hon O, Staal JB, Limpens J, Kuipers H, Overbeek SE, Zwinderman AH, Scholten RJ . β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials . Sports Medicine . 41 . 1 . 39–57 . January 2011 . 21142283 . 10.2165/11537540-000000000-00000 . 189906919 .
  39. Davis E, Loiacono R, Summers RJ . The rush to adrenaline: drugs in sport acting on the beta-adrenergic system . British Journal of Pharmacology . 154 . 3 . 584–97 . June 2008 . 18500380 . 2439523 . 10.1038/bjp.2008.164 .
  40. Web site: The 2010 Prohibited List International Standard . WADA . 20 October 2010 . dead . https://web.archive.org/web/20130911050811/http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/WADA_Prohibited_List_2010_EN.pdf . 11 September 2013 .
  41. Web site: The 2011 Prohibited List International Standard . WADA . 22 May 2012 . live . https://web.archive.org/web/20120513015917/http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf . 13 May 2012 .
  42. Book: Baselt R . Disposition of Toxic Drugs and Chemicals in Man . 8th . Biomedical Publications . 2008 . 33–35 . 978-0-9626523-6-3 .
  43. Bergés R, Segura J, Ventura R, Fitch KD, Morton AR, Farré M, Mas M, de La Torre X . Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment . Clinical Chemistry . 46 . 9 . 1365–75 . September 2000 . 10.1093/clinchem/46.9.1365 . 10973867 . https://web.archive.org/web/20110717111432/http://www.clinchem.org/cgi/content/abstract/46/9/1365 . live . 17 July 2011 . free .
  44. Schweizer C, Saugy M, Kamber M . Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete . Clinical Journal of Sport Medicine . 14 . 5 . 312–5 . September 2004 . 15377972 . 10.1097/00042752-200409000-00018 . 30402521 .
  45. Web site: Albuterol Sulfate. Rx List: The Internet Drug Index. 13 July 2014. live. https://web.archive.org/web/20140718041226/http://www.rxlist.com/albuterol-sulfate-drug/clinical-pharmacology.htm. 18 July 2014.
  46. Liewluck T, Selcen D, Engel AG . Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia . Muscle & Nerve . 44 . 5 . 789–94 . November 2011 . 21952943 . 3196786 . 10.1002/mus.22176 .
  47. Van Meerbeke JP, Sumner CJ . Progress and promise: the current status of spinal muscular atrophy therapeutics . Discovery Medicine . 12 . 65 . 291–305 . October 2011 . 22031667 .
  48. Lewelt A, Newcomb TM, Swoboda KJ . New therapeutic approaches to spinal muscular atrophy . Current Neurology and Neuroscience Reports . 12 . 1 . 42–53 . February 2012 . 22134788 . 3260050 . 10.1007/s11910-011-0240-9 .
  49. Hostrup M, Onslev J . The beta2 -adrenergic receptor - a re-emerging target to combat obesity and induce leanness? . The Journal of Physiology . 600 . 5 . 1209–1227 . March 2022 . 34676534 . 10.1113/JP281819 . 239457357 . free .
  50. Hostrup M, Jacobson GA, Jessen S, Lemminger AK . Anabolic and lipolytic actions of beta2 -agonists in humans and antidoping challenges . Drug Testing and Analysis . 12 . 5 . 597–609 . May 2020 . 31960603 . 10.1002/dta.2728 . 210842115 .
  51. Book: Plumb DC . Plumb's Veterinary Drug Handbook . Albuterol Sulfate . Stockholm, Wisconsin; Ames, Iowa . 2011 . 7th . Wiley . 9780470959640 . 24–25.
  52. Book: Clarke KW, Trim CM . Veterinary Anaesthesia E-Book . 28 June 2013 . Elsevier Health Sciences . 9780702054235 . 612 . live . https://web.archive.org/web/20170908175627/https://books.google.com/books?id=hZh5AAAAQBAJ&pg=PA612 . 8 September 2017 .
  53. Book: Cote E . Clinical Veterinary Advisor - E-Book: Dogs and Cats . Albuterol Toxicosis . 9 December 2014 . Elsevier Health Sciences . 9780323240741 . 45–46 . https://books.google.com/books?id=NmziBQAAQBAJ&pg=PR120 . live . https://web.archive.org/web/20170908175627/https://books.google.com/books?id=NmziBQAAQBAJ&pg=PR120 . 8 September 2017 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Salbutamol".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.